Media headlines about Recro Pharma (NASDAQ:REPH) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Recro Pharma earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 47.2439055771673 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Recro Pharma, Inc. (REPH) Major Shareholder Healthcare Master Fun Broadfin Sells 47,549 Shares (americanbankingnews.com)
- Recro Pharma, Inc. (REPH) Major Shareholder Sells $2,132,661.28 in Stock (americanbankingnews.com)
- Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Financial Statements and Exhibits (4-traders.com)
- $13.32 Million in Sales Expected for Recro Pharma, Inc. (REPH) This Quarter (americanbankingnews.com)
Recro Pharma (NASDAQ REPH) traded up $0.27 during trading hours on Monday, hitting $9.91. 120,900 shares of the stock were exchanged, compared to its average volume of 119,143. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59. Recro Pharma has a fifty-two week low of $5.81 and a fifty-two week high of $9.96.
A number of equities analysts have recently weighed in on REPH shares. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a research note on Wednesday, August 16th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research note on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $11.65.
In related news, major shareholder Healthcare Master Fun Broadfin sold 47,549 shares of the stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $9.64, for a total value of $458,372.36. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 544,813 shares of company stock worth $5,191,579. 21.60% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Recro Pharma (REPH) Earning Somewhat Favorable Press Coverage, Study Finds” was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.truebluetribune.com/2017/12/04/recro-pharma-reph-earning-somewhat-favorable-press-coverage-study-finds.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.